Chemotherapy-nave patients with ACC were allocated to the following treatment groups : group A , a bolus of 20 mg/m ( 2 ) LV and 425 mg/m ( 2 ) 5-FU for 5 days until progression/relapse , and upon progression treatment with weekly CPT-11 ( 100 mg/m ( 2 ) ) , and group B , CPT-11 followed at progression/relapse by 5-FU/LV at the same doses and schedules as in group A.
